Medidata vs Octozi (2026)
Both bring AI to trial data review, one from inside the capture platform and one from across it. Medidata's AI sits inside Rave: Medidata Plus, packaged since July 2026, covers study build, Clinical Data Studio for data review and safety signal detection, AI enabled audit trail review and the Dot assistant. Octozi sits across a study's systems, harmonizing EDC, safety, laboratory, CTMS, eCOA and IRT data on one workspace. Its agents clean data, review medical and safety data, reconcile and monitor, and draft queries reviewers accept, edit or reject, on models fine tuned from Llama 4. A study team standardized on Rave gets review where the data already lives; a team working across several systems gets a single workspace from Octozi.
- Data review, safety signals and audit trail review inside Rave.
- AI study build that generates forms, edit checks and synthetic test data.
- Certification documents on a public trust page.
- One workspace across EDC, safety, lab, CTMS, eCOA and IRT data.
- Agents that draft queries a reviewer accepts, edits or rejects, traced to the source.
- SOC 2 Type II, with customer data kept out of model training.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Medidata and Octozi are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Medidata | Octozi |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | Not recorded | 2024 |
| Headquarters | New York, New York | New York, New York, United States |
| Website | medidata.com | octozi.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Medidata, a Dassault Systemes brand based in New York, sells clinical trial software to drug and device sponsors and contract research organizations. The platform is anchored by Rave electronic data capture and spans study build, trial management, patient experience, imaging and data review, with about 2,300 customers.
Source: AI Health Index, September 2026
New York company applying AI agents to clinical trial data operations: data cleaning, medical data review, safety review and reconciliation, medical monitoring and clinical operations, across five modules on one workspace for the study team. It harmonizes EDC, safety, laboratory, CTMS, eCOA and IRT data with source traceability and pairs proprietary language models fine-tuned from Llama 4 with heuristic algorithms, flagging discrepancies and drafting queries that reviewers accept, edit or reject.
Source: AI Health Index, September 2026
Questions buyers ask
How do Medidata and Octozi work with the EHR?
Clinical Data Studio brings in non-Medidata sources, including third party laboratories and other data capture systems. Data flows one way, from the record into the trial; no named record system, marketplace listing or integration documentation shows a production connection to a specific EHR, and the exchanges are not named.
With Octozi, the platform harmonizes EDC, safety, laboratory, CTMS, eCOA and IRT data into one model with source traceability, and the company's positioning is to work with the systems study teams already use. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How are Medidata and Octozi priced and sold?
In Medidata's case, enterprise agreements with sponsors, contract research organizations and medtech companies are scoped by study count and module. Medidata Plus, launched in July 2026, packages the AI capabilities as one layer the company describes as a predictable investment rather than per-tool costs.
For Octozi, the company's economic model of a representative phase 3 oncology trial estimates $5.1 million saved per study, mostly from a five-day-earlier database lock, which a sponsor can compare with its own delay costs; it models a representative trial rather than measuring one. Sales are to sponsors and contract research organizations by demo request. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How do Medidata and Octozi handle patient data?
With Medidata, the trust and transparency page says the company does not use data for secondary purposes without the customer's explicit written permission, reviews every internal data use request, and runs a Data Collaboration Program in which aggregated, anonymized data sits in a separate environment.
In Octozi's case, the training exclusion matters for sponsors who will not expose unblinded trial data to a vendor that might learn from it. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Which settings and specialties do Medidata and Octozi cover?
The platform serves biopharmaceutical and medtech sponsors and contract research organizations across study design, build, execution and closeout, with therapeutic area solutions in oncology, vaccines and CNS; Health Record Connect also feeds Medidata Surgical Planning and real world data work that reaches beyond trials.
With Octozi, the platform covers the clinical trial data layer (data management, clinical science review, safety review and reconciliation, medical monitoring and clinical operations) for pharmaceutical, biotech and medtech sponsors and contract research organizations. The only published evaluation used synthetic data built from one phase 3 oncology trial. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
Both records were reviewed on this site in September 2026. Neither company publishes a price. Octozi's six fold faster review comes from a preprint on synthetic trial data.
Ask both how the model's drafted queries are checked on real studies, and what share reviewers reject.